|  |  |
| --- | --- |
| **Pharmacy and Therapeutics Committee**  Virtual Meeting  May 23, 2023  12:00 PM - 5:00 PM | |
| [**Zoom Meeting Registration**](https://ahcccs.zoom.us/webinar/register/WN_ZfWV5RuSR7iaiHktD6OzKA?_x_zm_rtaid=xhCiZxU6RvikOxapEx01bw.1683734906823.f74b144373e9c862ef10db92c363e3ce&_x_zm_rhtaid=508#/registration) | |
| **Time** | **Topic** |
| **12:00 PM** | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:10 PM** | **Minutes Review and Vote - P&T January 25, 2023:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:15 PM** | **Nineteen Supplemental Rebate Drug Class Reviews:** Clinical review by Hind Douiki, PharmD, Magellan   1. **Analgesics Agents**    1. Public Testimony: None 2. **Antibiotics - Inhaled**    1. Public Testimony: None 3. **Anticoagulants**    1. Public Testimony: None 4. **Antimigraine - CGRPs**    1. Oral Public Testimony:       1. Rochelle Yang    2. Written Public Testimony: None 5. **Antipsychotics - Atypical Long-Acting Injectables**    1. Oral Public Testimony:       1. Kenneth Berry    2. Written Public Testimony:       1. John Sarris       2. Kristin Sabetta – Antipsychotics in general       3. Miguel Tosado Rivera – Antipsychotics in general 6. **Antipsychotics - Oral Atypicals - 2nd Generation**    1. Oral Public Testimony:       1. Laura Anderson       2. Kenneth Berry       3. Ana McNabb       4. Heather Fremi    2. Written Public Testimony       1. Devin Wengert       2. James Reed       3. Kristin Sabetta - Antipsychotics in general       4. Miguel Tosado Rivera – Antipsychotics in general 7. **COPD**     1. Public Testimony: None 8. **Cytokine and CAM Antagonists**    1. Oral Public Testimony:       1. Melissa Sommers 9. **Epinephrine - Self-Injected**    1. Public Testimony: None 10. **Glucagon**     1. Oral Public Testimony:        1. Dena Bondugji        2. Rachel Shubitz 11. **Glucocorticoids - Inhaled**     1. Public Testimony: None 12. **Growth Hormone**     1. Public Testimony: None 13. **Hepatitis C Agents**      1. Public Testimony: None 14. **Hypoglycemics - Incretin Mimetics**     1. Oral Public Testimony: None     2. Written Public Testimony: None 15. **Hypoglycemics - Insulin and Related Agents**     1. Public Testimony: None 16. **Opioid Dependence Treatments**      1. Oral Public Testimony:        1. Kenneth Berry        2. Jake Nichols – Testimony for 2 drugs     2. Written Public Testimony: None 17. **Pancreatic Enzymes**     1. Public Testimony: None 18. **Progestational Agents**     1. Public Testimony: None 19. **Stimulants and Related Agents**     1. Public Testimony: None |
| **2:45 PM** | **New Drug Reviews: Hind Douiki,** PharmD, Magellan   1. **Joenja**    1. **Public Testimony – Brian Hartline** |
| **3:00 PM** | **Break & Executive Session:** Kristen Haloski**,** PharmD, AAHIVP, Magellan |
| **4:15 PM** | **Public Therapeutic Class Votes:** Hind Douiki, PharmD, Magellan |
| **4:45 PM** | **Biosimilar Update: Suzi Berman**   1. **Amjevita (Adalimumab-ATTO)** |
| **4:50 PM** | **Meeting Adjournment**  Future Meeting Dates: October 25, 2023, January 24, 2024 |